Stereotaxis, Inc. (STXS)
| Market Cap | 187.16M +10.5% |
| Revenue (ttm) | 32.38M +20.3% |
| Net Income | -22.91M |
| EPS | -0.25 |
| Shares Out | 97.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 388,560 |
| Open | 1.880 |
| Previous Close | 1.880 |
| Day's Range | 1.850 - 1.950 |
| 52-Week Range | 1.740 - 3.590 |
| Beta | 1.33 |
| Analysts | Strong Buy |
| Price Target | 4.00 (+108.33%) |
| Earnings Date | May 12, 2026 |
About STXS
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Na... [Read more]
Financial Performance
In 2025, Stereotaxis's revenue was $32.38 million, an increase of 20.28% compared to the previous year's $26.92 million. Losses were -$22.91 million, -9.62% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for STXS stock is "Strong Buy." The 12-month stock price target is $4.0, which is an increase of 108.33% from the latest price.
News
Stereotaxis Earnings Call Transcript: Q1 2026
Q1 2026 revenue declined year-over-year amid a transition from legacy products, but new robotic systems and catheters are gaining regulatory approvals and early commercial traction. Guidance for double-digit revenue growth and over $40 million in annual revenue is reiterated, with recurring revenue expected to drive profitability.
Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates
ST. LOUIS, May 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates...
Stereotaxis Announces First MAGiC Procedures in the United States
ST. LOUIS, April 22, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first pat...
Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026
ST. LOUIS, April 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will ...
Stereotaxis Transcript: M&A announcement
The acquisition of Robocath brings complementary robotic technology, accelerating the strategy to lead in endovascular procedures. The deal includes up to $45 million in payments, targets a $20–30 billion market, and expects break-even by year three post-close.
Stereotaxis to acquire Robocath, terms undisclosed
Stereotaxis (STXS) announced that it has entered into a definitive agreement to acquire Robocath. Stereotaxis estimates that Robocath will contribute approximately $2M in annual revenue during the fir...
Stereotaxis Announces Definitive Agreement to Acquire Robocath
ST. LOUIS and ROUEN, France, April 15, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today annou...
Stereotaxis receives FDA clearance for Synchrony system
Stereotaxis (STXS) announced that it has received FDA 510(k) clearance for the Synchrony system. “Synchrony and SynX are central to our digital surgery efforts to modernize the interventional lab with...
Stereotaxis Announces FDA Clearance and Launch of Synchrony System
ST. LOUIS, April 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has r...
Stereotaxis files $100M mixed securities shelf
16:26 EDT Stereotaxis (STXS) files $100M mixed securities shelf
Stereotaxis management to meet virtually with BTIG
Virtual Meeting to be held on March 24 hosted by BTIG.
Stereotaxis Earnings Call Transcript: Q4 2025
Delivered 36% Q4 revenue growth and launched new robotic and catheter products after key regulatory approvals. Manufacturing ramp and transition to proprietary catheters are underway, with double-digit revenue growth and margin expansion expected in 2026.
Stereotaxis reports Q4 EPS (6c), consensus (6c)
Reports Q4 revenue $8.64M, consensus $9.24M. System backlog at the start of 2026 is $9.1M. “The past year saw tremendous progress with significant regulatory approvals globally, advancement of a broad...
Stereotaxis sees FY26 revenue up double digits
The company said, “Stereotaxis (STXS) anticipates double digit revenue growth for the full year 2026. Both system and recurring revenue are expected to increase over the course of the year…
Stereotaxis Reports 2025 Full Year Financial Results
ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resu...
Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026
ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...
Stereotaxis announces launch of electrophysiology program at Klinikum Furth
Stereotaxis (STXS) announced the launch of a new robotic electrophysiology program at Klinikum Furth in Furth, Germany. Klinikum Furth is the first hospital in Germany to establish a leading heart…
Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program
ST. LOUIS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of ...
Stereotaxis reports FDA approval for MAGiC Ablation Catheter
Stereotaxis (STXS) announced it obtained U.S. Food and Drug Administration approval for the MAGiC Magnetic Interventional Ablation Catheter. “FDA approval of MAGiC is a significant milestone for Stere...
Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter
ST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U....
Stereotaxis initiated with an Outperform at Citizens
Citizens initiated coverage of Stereotaxis (STXS) with an Outperform rating and $4 price target Stereotaxis develops robotic platforms for use in endovascular surgeries, the analyst tells investors in...
Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference
ST. LOUIS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the compa...
Stereotaxis Earnings Call Transcript: Q3 2025
Stereotaxis reports Q3 EPS (7c), consensus (6c)
Reports Q3 revenue $7.46M, consensus $8.38M. “We continue to focus on driving commercial progress while advancing a robust portfolio of technologies through regulatory and development milestones,” sai...
Stereotaxis Reports 2025 Third Quarter Financial Results
ST. LOUIS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul...